10-05-2025
Applied Therapeutics to present full 12-month INSPIRE Phase 3 results
Applied Therapeutics (APLT) announced its late-breaking abstract for govorestat, or AT-007, has been selected for oral presentation at the Peripheral Nerve Society 2025 Annual Meeting, held May 17-20. The presentation will include full 12-month clinical results from the INSPIRE Phase 3 trial in SORD Deficiency, a subtype of Charcot-Marie-Tooth disease. It will also include new topline 18-month and 24-month data. The company previously shared topline 12-month data in February 2024.
Protect Your Portfolio Against Market Uncertainty
